Volume 22, Number 10—October 2016
Synopsis
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes
Table 2
Population age group, y, and HPVtype | No. studies† | Heterogeneity |
Prevalence ratio (95% CI) | |
---|---|---|---|---|
I2, % | p value | |||
≤19 | ||||
HPV types in nonavalent vaccine | 8 | |||
HPV31 | 6.4 | 0.381 | 0.73 (0.58–0.91) | |
HPV33 | 0 | 0.471 | 1.04 (0.78–1.38) | |
HPV45 | 5.5 | 0.387 | 0.96 (0.75–1.23) | |
HPV52 | 24.0 | 0.238 | 1.34 (1.13–1.59) | |
HPV58 | 0 | 0.727 | 1.01 (0.80–1.26) | |
Other high-risk HPV types | 8 | |||
HPV35 | 25.1 | 0.229 | – | |
HPV39 | 0 | 0.984 | 1.27 (1.05–1.54) | |
HPV51 | 43.6 | 0.088 | – | |
HPV56 | 74.3 | <0.001 | – | |
HPV59 | 66.8 | 0.004 | – | |
HPV68 | 0 | 0.690 | 1.26 (0.88–1.81) | |
Other possibly high-risk HPV types | 6 | |||
HPV26 | 0 | 0.478 | 1.63 (0.84–3.16) | |
HPV53 | 3.6 | 0.394 | 1.51 (1.10–2.06) | |
HPV70 | 23.6 | 0.257 | 1.34 (0.75–2.39) | |
HPV73 | 0 | 0.961 | 1.36 (1.03–1.80) | |
HPV82 |
49.0 |
0.081 |
– |
|
20–24 | ||||
HPV types in nonavalent vaccine | 8 | |||
HPV31 | 28.8 | 0.198 | – | |
HPV33 | 50.9 | 0.047 | – | |
HPV45 | 64.3 | 0.007 | – | |
HPV52 | 31.0 | 0.180 | – | |
HPV58 | 0 | 0.806 | 1.14 (0.99–1.31) | |
Other high-risk HPV types | 8 | |||
HPV35 | 7.9 | 0.369 | 1.07 (0.85–1.34) | |
HPV39 | 0 | 0.522 | 1.13 (1.00–1.28) | |
HPV51 | 49.8 | 0.052 | – | |
HPV56 | 82.6 | <0.001 | – | |
HPV59 | 63.6 | 0.007 | – | |
HPV68 | 35.6 | 0.145 | – | |
Other possibly high-risk HPV types | 6 | |||
HPV26 | 44.3 | 0.110 | – | |
HPV53 | 30.8 | 0.204 | – | |
HPV70 | 25.1 | 0.246 | – | |
HPV73 | 59.2 | 0.032 | – | |
HPV82 | 38.3 | 0.151 | – |
*HPV, human papillomavirus; –, prevalence ratio not calculated because of heterogeneity of data.
†Number of studies was the same for all HPV types within each category.
Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.